Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PX-866 + docetaxel
- Development stage
- Unknown
- Lead developer
- Oncothyreon
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PX-866 is an oral, irreversible, pan-isoform small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K), a key enzyme in the PI3K/AKT/mTOR signaling pathway that regulates cell proliferation, survival, adhesion, and motility. Docetaxel is a chemotherapy agent that acts as a microtubule inhibitor disrupting mitosis. The combination of PX-866 with docetaxel has been investigated primarily for treatment of advanced solid tumors including head and neck squamous cell carcinoma (HNSCC) and other refractory cancers. Clinical studies have shown the combination to be generally well tolerated without overlapping toxicities; however, phase 2 trials did not demonstrate significant improvement in progression-free survival or overall survival compared to docetaxel alone in unselected patient populations. The rationale for combining these drugs is based on preclinical synergy between PI3K inhibition by PX-866 and cytotoxic effects of docetaxel.
- Other names
- PX-866 + docetaxel
02
Targets
PI3K (Phosphoinositide-3-kinase regulatory subunit 6)
Beyond the preview
Go deeper on PX-866 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PX-866 + docetaxel.